Genzyme Transgenics
This article was originally published in The Gray Sheet
Executive Summary
Increase in credit facility by $15 mil. to a total of $24.6 mil. is arranged through a commitment from Fleet Bank. The Framingham, Massachusetts transgenic technology spin-off of Genzyme General also has received a commitment for a $5 mil. lease line of credit with Transamerica Technology Finance. The new capital strengthens the firm's financial position and will be used in part to refinance existing debt and for expansion of production facilities. The company is developing transgenic technology to enable development and production of recombinant proteins and monoclonal antibodies for medical uses
You may also be interested in...
US Payers Rate ICER Assessment Updates Using Real World Data As Potentially ‘High Impact’
ICON survey finds payers increasingly use ICER reports at multiple ‘touchpoints’ during the drug evaluation and decision-making process and the most common use reported in 2020 was as a reference in rebate and pricing negotiations.
Most Pharmacies Ready For COVID-19 Vaccines; Ultra-Cold Storage Still A Limitation
Results of a forthcoming APhA survey showed about one-third cannot store Pfizer/BioNTech's BNT162b2, but can handle Moderna's mRNA-1273.
Battery Failures From Improper Cleaning Lead To Class I Recall For Baxter Infusion Pumps
Baxter has recalled more than half a million infusion pumps due to concerns improper cleaning could cause their batteries to malfunction. The recall was designated as high-risk class I by the US FDA.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: